These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 22483936)

  • 1. Biomarkers of cell death applicable to early clinical trials.
    Dean E; Greystoke A; Ranson M; Dive C
    Exp Cell Res; 2012 Jul; 318(11):1252-9. PubMed ID: 22483936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.
    Garcia VM; Cassier PA; de Bono J
    Cancer Discov; 2011 Aug; 1(3):207-12. PubMed ID: 22586572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic biomarkers for molecular cancer therapeutics.
    Sarker D; Workman P
    Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From darkness to light with biomarkers in early clinical trials of cancer drugs.
    Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS
    Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of breast cancer apoptosis induced by chemotherapy and TRAIL.
    Leong S; McKay MJ; Christopherson RI; Baxter RC
    J Proteome Res; 2012 Feb; 11(2):1240-50. PubMed ID: 22133146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers in early cancer drug development: limited utility.
    Glassman RH; Ratain MJ
    Clin Pharmacol Ther; 2009 Feb; 85(2):134-5. PubMed ID: 19151638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Death receptor agonists as a targeted therapy for cancer.
    Wiezorek J; Holland P; Graves J
    Clin Cancer Res; 2010 Mar; 16(6):1701-8. PubMed ID: 20197482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker method validation in anticancer drug development.
    Cummings J; Ward TH; Greystoke A; Ranson M; Dive C
    Br J Pharmacol; 2008 Feb; 153(4):646-56. PubMed ID: 17876307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the outcomes: developing cancer therapeutics.
    Utku N
    Future Oncol; 2012 Jan; 8(1):87-103. PubMed ID: 22149037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy.
    Odoux C; Albers A
    Vitam Horm; 2004; 67():385-407. PubMed ID: 15110187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL receptor signaling and therapeutics.
    Abdulghani J; El-Deiry WS
    Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualification of imaging biomarkers for oncology drug development.
    Waterton JC; Pylkkanen L
    Eur J Cancer; 2012 Mar; 48(4):409-15. PubMed ID: 22226478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
    Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
    Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.